{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:21Z","timestamp":1761870381425,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.3816\/clml.2010.n.033","type":"journal-article","created":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T21:07:08Z","timestamp":1275080828000},"page":"211-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase I Study of Temozolomide and Laromustine (VNP40101M) in Patients With Relapsed or Refractory Leukemia"],"prefix":"10.3816","volume":"10","author":[{"given":"David","family":"Rizzieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khuda","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Karsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanton L.","family":"Gerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.033_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.033_bib2","series-title":"Hospital Medicine","first-page":"747","article-title":"Acute leukemia","author":"Rizzieri","year":"2000"},{"key":"10.3816\/CLML.2010.n.033_bib3","first-page":"998","article-title":"Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia","volume":"89","author":"Ferrara","year":"2004","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.033_bib4","first-page":"3033","article-title":"1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2(methylamino)carbonylhydrazine (101m): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity","volume":"61","author":"Finch","year":"2001","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.033_bib5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.leukres.2009.01.025","article-title":"Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin","volume":"33","author":"Morris","year":"2009","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.033_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/jm00382a027","article-title":"Synthesis and evaluation of N,N-bis(arylsulfonyl)hydrazines as antineoplastic agents","volume":"28","author":"Shyam","year":"1985","journal-title":"J Med Chem"},{"key":"10.3816\/CLML.2010.n.033_bib7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/jm00157a041","article-title":"1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity","volume":"29","author":"Shyam","year":"1986","journal-title":"J Med Chem"},{"key":"10.3816\/CLML.2010.n.033_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0006-2952(99)00328-7","article-title":"Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas","volume":"59","author":"Penketh","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CLML.2010.n.033_bib9","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-03-0738","article-title":"A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia","volume":"10","author":"Giles","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.033_bib10","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1158\/1078-0432.CCR-05-1070","article-title":"Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia","volume":"11","author":"Giles","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.033_bib11","first-page":"5375","article-title":"Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis (2-chloroethyl) nitrosourea","volume":"56","author":"Liu","year":"1996","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.033_bib12","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2002.01.030","article-title":"Phase I study of temozolomide in relapsed\/refractory acute leukemia","volume":"20","author":"Seiter","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.033_bib13","first-page":"2309","article-title":"Temozolomide: the effect of once-and twice-a-day dosing on tumor tissue levels of the DNA repair protein O6-alkylguanine-DNA-alkyltransferase","volume":"7","author":"Spiro","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.033_bib14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0022-3565(25)20982-X","article-title":"In vitro inactivation of human O6-alkylguanine DNA alkyltransferase by antitumor triazene compounds","volume":"279","author":"Lacal","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3816\/CLML.2010.n.033_bib15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1172\/JCI112215","article-title":"O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells","volume":"76","author":"Gerson","year":"1985","journal-title":"J Clin Invest"},{"key":"10.3816\/CLML.2010.n.033_bib16","first-page":"3025","article-title":"Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer","volume":"6","author":"Schilsky","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.033_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10408449991349276","article-title":"Glutathione redox system in oxidative lung injury","volume":"29","author":"Rahman","year":"1999","journal-title":"Crit Rev Toxicol"},{"key":"10.3816\/CLML.2010.n.033_bib18","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.bcp.2005.02.016","article-title":"Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs cloretazine and BCNU","volume":"69","author":"Rice","year":"2005","journal-title":"Biochem Pharmacol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:31Z","timestamp":1761870151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S2152265011700088"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.033","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Study of Temozolomide and Laromustine (VNP40101M) in Patients With Relapsed or Refractory Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}